News

Event Start Date: SEP 23, 2025 Share

The CAR-TCR Summit is the world’s leading conference dedicated to the end-to-end coverage of every stage of cell therapy development. Microbubbles are an effective solution to cell separation challenges in cell therapy and data demonstrating various ways microbubbles are being deployed in cell therapy workflows will be shown at Akadeum’s poster on display beginning the first day of the conference. Akadeum’s team will be onsite, ready to discuss how users …

Event Start Date: OCT 6, 2025 Share

Akadeum is honored to be selected to moderate a panel on a critical topic—quality, speed, and cost—in addition to being selected for a company presentation at this year’s Cell & Gene Meeting on the Mesa in Phoenix, AZ. The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference, bringing together top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing …

Event Start Date: AUG 12, 2025 Share

Akadeum is proud to be a sponsor for the upcoming Hope Is Not a Workflow: Addressing the Hard Truths of CGT Manufacturing symposium, cohosted by Excellos, Pluristyx, and Teknova. This full-day event will bring together leaders across the cell and gene therapy (CGT) ecosystem to explore practical, scalable solutions for advancing novel therapeutics from discovery through commercialization. Held at the Excellos Headquarters in downtown San Diego, the symposium features a …

Updated on Jul 13, 2025 | Published on Jun 8, 2025 Share

Not every cell therapy lab can access high-throughput automation, but that shouldn’t mean sacrificing quality, consistency, or scalability. For researchers working with limited resources or those who need flexibility within their workflow, Akadeum Life Sciences offers a better way to isolate high-quality T cells. With Akadeum’s microbubble kits, you can achieve high-purity, untouched T cell populations in under an hour without magnets or specialized equipment. The closed-system, in-bag workflow supports …

Event Start Date: JUN 16, 2025 Share

Meet Akadeum at BIO International Convention 2025, Boston, June 16–19, Boston Convention and Exhibition Center. We’re excited to share that our Account Executive, Charlie Dugas, will be representing Akadeum Life Sciences at the 2025 BIO International Convention in Boston. You can find Charlie at the Akadeum kiosk within the MichBio Pavilion, booth #2835. If you’re working in the cell therapy space and looking to upgrade your workflow with a gentle, …

Updated on Jul 13, 2025 | Published on Jun 5, 2025 Share

Imagine unlocking greater flexibility in your cell therapy workflow while preserving cell health, improving yield, and reducing complexity without overhauling your existing equipment. That’s precisely what Akadeum Life Sciences’ microbubble technology makes possible. In a recent case study with the Lonza Cocoon® Platform, Akadeum’s GMP microbubbles enabled fully automated T cell enrichment from cryopreserved leukopaks—no magnets, beads, or compromise. Microbubble-based separation can modernize cell manufacturing while maintaining compatibility with closed-system, …

Event Start Date: MAY 13, 2025 Share

Akadeum is participating alongside partners at the forefront of the cell therapy space in the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting in New Orleans, May 13th-16th. Throughout the conference there are multiple opportunities for interested parties to engage and learn more about moving away from magnetics to truly accelerate the next generation of cell therapies, how to use GMP grade microbubble cell separation with any …

Updated on Jul 13, 2025 | Published on Mar 14, 2025 Share

Chronic Lymphocytic Leukemia (CLL) is a complex blood cancer that affects the immune system by disrupting normal blood cell function and production. While traditional treatments such as chemotherapy and targeted small molecule therapies have been widely used, they often fall short for patients with aggressive or relapsed CLL. Chimeric Antigen Receptor (CAR) T cell therapy has emerged as a promising approach, offering the potential for durable remission. However, manufacturing effective …

Updated on Jul 13, 2025 | Published on Mar 5, 2025 Share

Multiple Myeloma (MM) is a cancer of plasma cells that disrupts normal immune function and blood cell production. While traditional treatments such as chemotherapy and immunomodulatory drugs have helped manage the disease, relapse remains a significant challenge. Some recent advances in Chimeric Antigen Receptor (CAR) T cell therapy target the B cell maturation antigen (BCMA) on the cells’ surface. These therapies have shown promising results, offering new hope for patients …

Updated on May 19, 2025 | Published on Feb 12, 2025 Share

Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin’s lymphoma (NHL), accounting for 30-40% of cases globally. While treatments like chemotherapy, including the R-CHOP regimen, can lead to remission in many patients, relapsed or refractory cases remain challenging, with limited long-term options. CAR T cell therapy transforms the treatment of DLBCL, providing renewed hope to patients by harnessing the body’s immune system to eliminate cancerous cells. …